Dose differences between patients treated with MR-only, CT-only, or MR-CT fusion radiotherapy for prostate cancer
British Journal of Radiology · 01.12.2025 · 98 (1176) · 2099-2105
DOI: 10.1093/bjr/tqaf159 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Radiology, online erschienen am 16.07.2025. Verfasst von Jonathan J Wyatt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, NE7 7DN, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Tomography, X-Ray Computed, Radiotherapy Planning, Computer-Assisted. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Magnetic Resonance (MR)-only radiotherapy has been clinically implemented but its dose impact has not been assessed in clinical practice. This study evaluated the volume and dose differences between patients treated with CT-only, MR-CT fusion, or MR-only prostate radiotherapy pathways.
Methods
Four hundred fifty-four patients from a single centre were treated using MR-only (n = 96), CT-only (n = 248), or MR-CT (n = 110) pathways. Patients were selected for different pathways based solely on geographic location and treatment date. Patients were contoured by the same group of delineators and were planned for 60 Gy in 20 fractions by an automated planning algorithm. Clinical Target Volume (CTV), bladder, penile bulb and rectum volumes, and clinical dose constraints were compared with Kurshkal-Wallis tests, adjusted for multiple testing with a P<.05 significance level.
Results
Median MR-only CTVs were 5 cm3 smaller than CT-only (P=.004). Penile bulb Dmean was 12.0 Gy (CT-only), 9.1 Gy (MR-CT), and 5.9 Gy (MR-only, P<.001), with 79.0%, 90.9%, and 95.8% of patients within constraint. Rectum D2 cm3 was 57.4 Gy (CT-only), 57.6 Gy (MR-CT), and 56.5 Gy (MR-only, P<.001), with 35.1%, 20.9%, and 56.2% of patients within rectum V60 Gy constraint.
Conclusions
The MR-only pathway produced significant reductions of 13% in CTV volume, 51% in penile bulb Dmean, and 2% in rectum D2 cm3 compared to CT-only. Advances in knowledge The dose benefit from MR-only has been assessed in clinical practice, demonstrating significant reductions in penile bulb and rectum doses compared to both CT-only and MR-CT pathways. This suggests the MR-only pathway is required to provide the full benefit of MR contouring to reduce toxicities from prostate radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, NE7 7DN, United Kingdom.
- Translational and Clinical Research Institute, Newcastle University, Newcastle, NE4 5PL, United Kingdom.
ORCID-Profile: Jonathan J Wyatt
Zitieren
APA
Wyatt, J. J., Hedley, S., Richmond, N., West, S., Brooks-Pearson, R. L., Wintle, T., & Pearson, R. A. (2025). Dose differences between patients treated with MR-only, CT-only, or MR-CT fusion radiotherapy for prostate cancer. British Journal of Radiology, 98(1176), 2099-2105. https://doi.org/10.1093/bjr/tqaf159
Vancouver
Wyatt JJ, Hedley S, Richmond N, West S, Brooks-Pearson RL, Wintle T, et al. Dose differences between patients treated with MR-only, CT-only, or MR-CT fusion radiotherapy for prostate cancer. British Journal of Radiology. 2025;98(1176):2099-2105. doi:10.1093/bjr/tqaf159
BibTeX
@article{Wyatt2025,
author = {Wyatt, Jonathan J and Hedley, Stephen and Richmond, Neil and West, Serena and Brooks-Pearson, Rachel L and Wintle, Tracy and Pearson, Rachel A},
title = {Dose differences between patients treated with MR-only, CT-only, or MR-CT fusion radiotherapy for prostate cancer},
journal = {British Journal of Radiology},
year = {2025},
volume = {98},
number = {1176},
pages = {2099--2105},
doi = {10.1093/bjr/tqaf159}
}
EUVIMED